Kit and method for detecting Streptococcus pyogenes
Through the detection method of streptococci pyogenes combined with MCDA-CRISPR/Cas12a system, the problem of long detection time and low sensitivity in the prior art is solved, and fast and visual detection is achieved, which is suitable for applications in non-hospital occasions and areas with limited resources. It has high sensitivity and high specificity.
Patent Information
- Application Number
- CN202411328724.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-24
AI Technical Summary
The existing detection methods for streptococcal pyogenes have problems such as long time consumption, low sensitivity, expensive equipment and professional technical personnel, and are difficult to widely use in non-hospital occasions and in areas with limited resources.
Using the MCDA-CRISPR/Cas12a system, the multi-cross-substitution amplification technology and CRISPR/Cas12a detection technology are combined, and the side-strand cleavage activity of Cas12a is activated by MCDA primers and gRNA, and the ssDNA fluorescent probe is combined to achieve rapid and visualized streptococcal pyogenes. Test.
It realizes rapid, high sensitivity and high specificity detection of Streptococcus pyogenes, and can complete the detection within 45 minutes, with a sensitivity of 45fg and a specificity of 100%. It does not require expensive instruments, is simple to operate, and is suitable for large-scale promotion and application.
Smart Images

Figure CN118834978B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of molecular biology detection, and in particular to a kit and a method for detecting Streptococcus pyogenes. Background Art
[0002] Streptococcus pyogenes, also known as group A beta-hemolytic streptococcus (GAS), is the most common pathogen causing acute pharyngitis in children. In children aged 5-15 years, about 15%-30% of pharyngitis is caused by GAS. In addition, pharyngitis caused by GAS can lead to various complications, including otitis media, tonsillar abscesses, sinusitis, impetigo, sepsis, scarlet fever, and severe invasive infections such as sepsis, necrotizing fasciitis, and streptococcal toxic shock syndrome (STSS). Repeated infection with GAS can also cause autoimmune diseases such as acute rheumatic fever, rheumatic heart disease (RHD), and acute post-streptococcal glomerulonephritis. It is reported that early and effective antibiotic treatment can shorten the course of the disease by 1-2 days, reduce the severity of complications, relieve symptoms, and prevent the spread of the disease. Rapid and early identification of GAS infection helps to use antibiotics for early and rational treatment and avoid the abuse of antibiotics in patients with non-streptococcal pharyngitis.
[0003] GAS pharyngitis and viral pharyngitis have similar symptoms and are difficult to differentiate clinically through physical examination. Throat swab culture and rapid antigen detection test (RADT) are the main laboratory diagnostic methods for diagnosing suspected GAS pharyngitis in children over 3 years old. However, the culture method is time-consuming, usually requiring 18-48 hours, and the culture results are easily affected by specimen collection, storage, transportation and antibiotic use. And the sensitivity is low, only 72%-87%. RADT can diagnose GAS infection in a short time, but its sensitivity is low and there are false negative results. According to the recommendations of the Infectious Diseases Society of America, negative RADT results in children and adolescents should be confirmed by throat culture. PCR-based methods can provide more accurate results for patients with suspected GAS pharyngitis, and there is no need for subsequent verification of negative results. However, this technology requires more expensive thermal cycling equipment such as PCR instruments to amplify the sequence, and requires experienced technicians to analyze the results, which limits its widespread application in non-hospital settings and areas with limited resources.
[0004] Therefore, finding GAS detection methods and kits that can be used anytime and anywhere, are simple and convenient to operate, low in cost, rapid, highly sensitive and highly specific has become a research hotspot. Summary of the invention
[0005] In order to solve at least one of the above technical problems, the present invention provides a kit and method for detecting Streptococcus pyogenes.
[0006] As one aspect, the present invention provides a kit for detecting Streptococcus pyogenes, the kit comprising: MCDA primers; the MCDA primers comprise a displacement primer pair, a cross primer pair, a first amplification primer pair, a second amplification primer and a third amplification primer pair; the displacement primer pair comprises a forward displacement primer F1 having a sequence as shown in SEQ ID NO.1 and a reverse displacement primer F2 having a sequence as shown in SEQ ID NO.2; the cross primer pair comprises a forward cross primer CP1 having a sequence as shown in SEQ ID NO.3 and a reverse cross primer CP2 having a sequence as shown in SEQ ID NO.4; the first amplification primer pair comprises a first reverse amplification primer D1 having a sequence as shown in SEQ ID NO.5 and a first forward amplification primer D2 having a sequence as shown in SEQ ID NO.6; the second amplification primer pair comprises a second reverse amplification primer C1 having a sequence as shown in SEQ ID NO.7 and a second forward amplification primer C2 having a sequence as shown in SEQ ID NO.8; the third amplification primer pair comprises a third reverse amplification primer R1 having a sequence as shown in SEQ ID NO.9 and a third reverse amplification primer R2 having a sequence as shown in SEQ ID NO.10; The third forward amplification primer R2 shown in NO.10; gRNA; the sequence of gRNA is shown in SEQ ID NO.11; Cas12a; and, ssDNA fluorescent probe; the sequence of the ssDNA fluorescent probe is shown in SEQ ID NO.12.
[0007] In some embodiments of the present invention, the kit further comprises: 2× reaction buffer, NEB endonuclease reaction buffer, Bst 2.0 DNA polymerase and double distilled water; the reaction buffer is a mixture of tris(hydroxymethyl)aminomethane hydrochloride, KCl, MgSO4, (NH4)2SO4, polyoxyethylene sorbitan monolaurate, (carboxymethyl)trimethylamine inner salt and deoxyribonucleotides; the endonuclease reaction buffer is a mixture of NaCl, tris(hydroxymethyl)aminomethane hydrochloride, MgCl2 and recombinant albumin.
[0008] In some embodiments of the present invention, the composition of 2× reaction buffer is:
[0009] 40 mM Tris-HCl (pH 8.8);
[0010] 20 mM KCl;
[0011] 16 mMMgSO4;
[0012] 20 Mm(NH4)2SO4;
[0013] 0.2% polyoxyethylene sorbitan monolaurate (Tween-20);
[0014] 1.6 M (carboxymethyl)trimethylamine inner salt (Betaine);
[0015] 2.8 mM / each deoxyribonucleotide (dNTPs).
[0016] In some embodiments of the present invention, the endonuclease reaction buffer is 2×NEBuffer r2.1, wherein 1×NEBuffer r2.1 (NEB endonuclease reaction buffer) is composed of:
[0017] 50 mM NaCl;
[0018] 10 mM Tris-HCl;
[0019] 10 mM MgCl2;
[0020] 100 µg / mL recombinant albumin.
[0021] As another aspect, the present invention provides a method for detecting Streptococcus pyogenes using the above-mentioned kit, the method comprising: using a multiple cross-displacement amplification method, using MCDA primers to amplify the DNA of the sample to be tested to prepare an amplification product; gRNA and Cas12a protein are compounded to form a Cas12a-gRNA binary complex; the amplification product, the Cas12a-gRNA binary complex and an ssDNA fluorescent probe are incubated to obtain an incubation product; the fluorescent signal of the incubation product is detected; and it is determined whether Streptococcus pyogenes is present.
[0022] In some embodiments of the present invention, the amplification step includes: MCDA primers, 2× reaction buffer, Bst 2.0 A mixture of DNA polymerase, DNA of the sample to be tested, and double distilled water is reacted at 59-68°C.
[0023] In some embodiments of the present invention, the step of complexing gRNA and Cas12a protein includes: mixing Cas12a and gRNA, adding them to endonuclease reaction buffer, and incubating at 37° C. for 8-10 minutes to obtain a Cas12a-gRNA binary complex.
[0024] In some embodiments of the present invention, the step of incubating the amplified product, the Cas12a-gRNA binary complex and the ssDNA fluorescent probe comprises: incubating a mixture of the amplified product, the Cas12a-gRNA binary complex, the ssDNA fluorescent probe, the endonuclease reaction buffer and double distilled water at 37° C. to shear the ssDNA fluorescent probe for 5-15 minutes.
[0025] In some embodiments of the present invention, the method for detecting the fluorescence signal of the incubation product includes: detecting the fluorescence value using a real-time fluorescence system; or observing the fluorescence signal under blue light irradiation after the incubation reaction is completed.
[0026] In some embodiments of the present invention, the method for determining whether Streptococcus pyogenes is present includes: if a fluorescent signal is detected, Streptococcus pyogenes is present, and if no fluorescent signal is detected, Streptococcus pyogenes is not present.
[0027] The technical solution provided by the embodiment of the present invention has the following advantages:
[0028] The kit and method of Streptococcus pyogenes based on MCDA-CRISPR / Cas12a in the embodiment of the present invention, based on GAS-related genes, combines MCDA and CRISPR systems to construct a platform for detecting the SpeB gene, specifically using MCDA to specifically amplify the SpeB gene to generate an amplification product that activates the side chain cleavage activity of Cas12a under the guidance of gRNA, thereby breaking the single-stranded DNA simultaneously labeled with the FAM fluorescent group and the quenching group, thereby releasing an obvious fluorescent signal to realize GAS detection.
[0029] The detection kit and method of the embodiment of the present invention do not need to rely on expensive large instruments, and an ordinary constant temperature water bath can realize the detection process.
[0030] The detection results of the detection kit and method of the embodiments of the present invention are visualized and can be read with the naked eye, which is simple to operate and suitable for large-scale promotion and application.
[0031] The detection kit and method of the embodiment of the present invention have high accuracy and short time required, and can quickly detect the lower limit of GAS as 45fg, with a specificity of 100%. The entire detection process includes MCDA amplification (40min) and CRISPR-Cas12a detection (5min), which can be completed in 45min, thereby quickly helping patients with pharyngitis suspected of GAS infection to make a diagnosis, use antibiotics for treatment as early as possible, shorten the course of the disease, and alleviate symptoms.
[0032] The detection kit and method of the embodiment of the present invention are based on the powerful side chain cleavage activity of the CRISPR-Cas12a cleavage system, which greatly improves the sensitivity of detection. The previous MCDA combined with polymer nano lateral flow biosensor (LFB) method had a detection sensitivity of 200 fg (per reaction), while the detection sensitivity of the present invention is 45 fg (per reaction).
[0033] In summary, the detection kit and method of the embodiments of the present invention provide a rapid, highly sensitive, and highly specific detection method for detecting GAS pharyngitis, which is free from the dependence on precision instruments, is easy to read, and is not restricted by location. It can improve the early detection rate of GAS, help doctors quickly and early identify GAS pharyngitis, thereby rationally using antibiotics for treatment and avoiding the abuse of antibiotics in patients with non-streptococcal pharyngitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the invention and, together with the description, serve to explain the principles of the invention.
[0035] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.
[0036] Figure 1 This is a schematic diagram of an embodiment of a method for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a of the present invention;
[0037] Figure 2 This is a diagram showing the detection working principle of an embodiment of a method for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a of the present invention;
[0038] Figure 3 A graph showing the change in turbidity over time of MCDA amplification of the first set of primers in an embodiment of the method for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a of the present invention;
[0039] Figure 4 A graph showing the change in turbidity over time of MCDA amplification of the second set of primers in an embodiment of the method for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a of the present invention;
[0040] Figure 5 A graph showing the change in turbidity over time of MCDA amplification of the third set of primers in an embodiment of the method for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a of the present invention;
[0041] Figure 6 A graph showing the change in turbidity over time of MCDA amplification of the fourth set of primers in an embodiment of the method for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a of the present invention;
[0042] Figure 7 A graph showing the change in turbidity over time of MCDA amplification of the fifth set of primers in an embodiment of the method for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a of the present invention;
[0043] Figure 8 A graph showing the change in turbidity over time of MCDA amplification of the sixth set of primers in an embodiment of the method for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a of the present invention;
[0044] Fig. 9 This is a schematic diagram of the locations of the MCDA primer binding site and the gRNA recognition site in the target gene SpeB of Streptococcus pyogenes according to an embodiment of the present invention;
[0045] Fig.10 This is the evaluation result of the feasibility of the GAS-MCDA-CRISPR method of the embodiment of the present invention;
[0046] Fig.11 This is a graph showing the experimental results of the optimal MCDA reaction temperature according to an embodiment of the present invention;
[0047] Fig.12 This is a graph showing the experimental results of CRISPR-Cas12a shearing time according to an embodiment of the present invention;
[0048] Fig.13 This is a graph showing the experimental results of the sensitivity of the MCDA-CRISPR method according to an embodiment of the present invention;
[0049] Fig.14 This is a graph showing the experimental results of the specificity of the MCDA-CRISPR method according to an embodiment of the present invention;
[0050] Fig.15 This is a graph showing the experimental results of using the MCDA-CRISPR method of an embodiment of the present invention for clinical sample verification. DETAILED DESCRIPTION
[0051] In order to more clearly understand the above-mentioned objectives, features and advantages of the present invention, the scheme of the present invention will be further described below. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
[0052] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present invention, rather than all of the embodiments.
[0053] Chinese patent CN104946744A discloses an isothermal nucleic acid amplification technology, which is named multiple cross displacement amplification (MCDA). It does not require template thermal denaturation and expensive thermal cycling equipment. It only needs a metal bath or water bath that can be heated at a constant temperature to operate. The amplification system only needs a constant temperature displacement enzyme, and nucleic acid amplification can be achieved within 40 minutes. It has the advantages of fast amplification reaction, sensitive reaction, and high specificity. In the MCDA system, there are 10 primers to identify the target sequence, including a pair of cross primers (CP1 and CP2), a pair of displacement primers (F1 and F2) and 3 pairs of amplification primers (D1, C1, R1, D2, C2 and R2), so as to ensure the specificity of the amplification reaction, and a single DNA polymerase with chain displacement activity can be used to amplify the target template at a constant temperature, with low equipment requirements and high amplification efficiency. Conventional methods for detecting MCDA amplification products mainly include real-time fluorescence acquisition and gel electrophoresis. The former requires a precise fluorescence acquisition device, and the latter takes a long time to operate. Both are subject to certain limitations in the field of on-site detection. Visual detection methods have the advantages of easy operation and intuitive results, and have great advantages in the field of on-site detection. The components in the reaction system (such as pyrophosphate ions, magnesium ions, hydrogen ions, etc.) change significantly before and after the reaction, and the results can often be visually judged by calcein method, turbidity method, pH dye method, etc., but such methods cannot eliminate the interference caused by non-specific amplified nucleic acid fragments, affecting the accuracy of detection.
[0054] The clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein (Cas) (CRISPR / Cas) system has shown significant advantages and potential in the field of molecular detection. Among them, the principle of using the CRISPR / Cas system for molecular diagnosis is based on its ability to accurately identify the target sequence and the side branch cutting activity of Cas proteins (such as Cas12a, Cas12b, and Cas13a). Among them, the Cas12a protein is an RNA-guided DNA targeting enzyme. When the Cas12a-gRNA binary complex recognizes the complementary target sequence and the adjacent PAM site (TTTN) under the guidance of gRNA, the side chain cutting activity of the Cas12a protein is activated, thereby rapidly and non-specifically cleaving the surrounding non-target single-stranded DNA (ssDNA) (labeled with fluorescent groups and quenchers). The broken ssDNA releases a large amount of fluorescent signals, which can be recorded by a real-time fluorescence instrument, or directly identified by the naked eye under blue light. However, the detection sensitivity of a single CRISPR-Cas12a system is low.
[0055] Therefore, combining multiple cross-displacement amplification with CRISPR / Cas12a detection technology can solve the disadvantage of low sensitivity of CRISPR detection system; at the same time, only after the gRNA sequence binds to the complementary target sequence will its side chain cleavage activity be stimulated, thereby avoiding false positive results caused by nonspecific amplification and further improving the specificity of detection. Relying on the high sequence dependence and efficient side chain cleavage activity of the CRISPR / Cas12a system, rapid, high-sensitivity and high-specificity detection of Streptococcus pyogenes can be achieved.
[0056] According to an embodiment of one aspect of the present invention, a kit for detecting Streptococcus pyogenes is provided, the kit comprising: MCDA primers; the MCDA primers comprising a displacement primer pair, a cross primer pair, a first amplification primer pair, a second amplification primer pair and a third amplification primer pair; the displacement primer pair comprises a forward displacement primer F1 having a sequence as shown in SEQ ID NO.1 and a reverse displacement primer F2 having a sequence as shown in SEQ ID NO.2; the cross primer pair comprises a forward cross primer CP1 having a sequence as shown in SEQ ID NO.3 and a reverse cross primer CP2 having a sequence as shown in SEQ ID NO.4; the first amplification primer pair comprises a first reverse amplification primer D1 having a sequence as shown in SEQ ID NO.5 and a first forward amplification primer D2 having a sequence as shown in SEQ ID NO.6; the second amplification primer pair comprises a second reverse amplification primer C1 having a sequence as shown in SEQ ID NO.7 and a second forward amplification primer C2 having a sequence as shown in SEQ ID NO.8; the third amplification primer pair comprises a third reverse amplification primer R1 having a sequence as shown in SEQ ID NO.9 and a third reverse amplification primer R2 having a sequence as shown in SEQ ID NO.10; The third forward amplification primer R2 shown in NO.10; gRNA; the sequence of gRNA is shown in SEQ ID NO.11; Cas12a; and, ssDNA fluorescent probe; the sequence of the ssDNA fluorescent probe is shown in SEQ ID NO.12.
[0057] The detection kit for Streptococcus pyogenes based on MCDA-CRISPR / Cas12a in the embodiment of the present invention has a simple and rapid operation process, high amplification efficiency, high sensitivity and good specificity; and the results can be read visually with the naked eye, the interpretation is more accurate and objective, the operation is simple, the repeatability is good, and it has good application prospects.
[0058] In some embodiments of the present invention, a PAM sequence is inserted into the cross primer pair, wherein the PAM sequence is TTTG.
[0059] In some embodiments of the present invention, the MCDA amplification technology is combined with the CRISPR-Cas12a detection technology for rapid detection of GAS, named GAS-MCDA-CRISPR.
[0060] In some embodiments of the present invention, the workflow of the GAS-MCDA-CRISPR detection method is as follows Figure 1 As shown, specifically: first, MCDA specifically amplifies the SpeB gene to generate an amplification product; then, the amplification product activates the side chain cleavage activity of Cas12a under the guidance of gRNA to break the single-stranded DNA simultaneously labeled with the FAM fluorescent group and the quenching group, thereby releasing an obvious fluorescent signal to realize GAS detection.
[0061] In some embodiments of the present invention, the detection principle of the GAS-MCDA-CRISPR detection method is as follows Figure 2 As shown, the method specifically includes the following steps: (1) extracting the genomic DNA of the target gene Streptococcus pyogenes; (2) amplifying the genomic DNA of Streptococcus pyogenes by the multiple cross-displacement amplification (MCDA) method to obtain an amplified product; (3) synthesizing the Cas12a-gRNA binary complex with gRNA and Cas12a protein; (4) the amplified product of step (2) and the Cas12a-gRNA binary complex of step (3) combine to form a ternary complex to stimulate the side chain cleavage activity of Cas12a protein; (5) the ternary complex obtained in step (4) cleaves the ssDNA fluorescent probe molecule to obtain a cleavage product; (6) labeling the cleavage product of step (5) with a fluorescent group and a quenching group to release a fluorescent signal for fluorescence detection.
[0062] In some embodiments of the present invention, the reagent combination for detecting Streptococcus pyogenes based on MCDA-CRISPR / Cas12a fluorescence visualization includes the following: MCDA primers targeting the SpeB gene; gRNA, ssDNA probe molecules and CRISPR-Cas12a proteins corresponding to the amplification products of the SpeB gene primers.
[0063] In some embodiments of the present invention, a set of MCDA primers, gRNA and ssDNA fluorescent probe molecules are designed for the SpeB gene of GAS (an exotoxin B gene encoding a cysteine protease), and the sensitivity and specificity of this method for detecting GAS are evaluated by optimizing the detection conditions, and this method is used for verification of clinical samples.
[0064] In some embodiments of the present invention, a MCDA primer for the SpeB gene of GAS is provided. The MCDA primer includes a portion of the SpeB gene fragment that can be used for specific amplification. The MCDA primers are SpeB-F1, SpeB-F2, SpeB-CP1, SpeB-CP2, SpeB-C1, SpeB-C2, SpeB-D1, SpeB-D2, SpeB-R1, and SpeB-R2.
[0065] In some embodiments of the present invention, a gRNA corresponding to the MCDA amplification target sequence of the SpeB gene designed according to the base pairing principle and the PAM sequence (TTTN) is provided.
[0066] In some embodiments of the present invention, a MCDA-CRISPR detection method for detecting GAS based on a throat swab as a sample is provided; whether there is GAS infection is determined according to the presence or absence of a fluorescent signal in the result.
[0067] In some embodiments of the present invention, the detection method of Streptococcus pyogenes based on fluorescent visualization of MCDA-CRISPR / Cas12a is achieved by the following steps: (1) amplifying the SpeB gene of GAS by MCDA amplification technology and obtaining an amplified product; (2) the CRISPR-Cas12a diagnostic system binds to the amplified product under the guidance of gRNA, stimulates the side chain cleavage activity of Cas12a protein, cuts the ssDNA fluorescent probe molecule, and emits a fluorescent signal; (3) reporting the fluorescent signal by a real-time fluorescence detection system or observing by naked eyes whether the reaction tube emits a fluorescent signal under blue light.
[0068] The steps involved in the implementation of the present invention are:
[0069] The genomic DNA of Streptococcus pyogenes and other bacteria was extracted using the EasyPure Bacterial Genomic DNA Kit (Enzymatic Hydrolysis) DNA Extraction Kit according to the instructions. The standard strain of GAS was cultured in a blood agar dish for 18-24 hours, and the culture was observed and the colonies were identified. The cultured colonies were used to extract GAS genomic DNA. The concentration and purity of the genomic DNA were determined using an ultraviolet spectrophotometer. The genomic DNA of GAS was diluted continuously (900 pg, 90 pg, 9pg, 900 fg, 90 fg, 45 fg, 22.5fg). It was packaged in small amounts and stored at -20°C for later use. The serially diluted GAS genomic DNA was used for primer screening for MCDA amplification, exploration of the optimal temperature, and evaluation of sensitivity. The specificity of GAS-MCDA-CRISPR was evaluated using DNA templates of common pathogens and other pathogens of conditional pathogens. Throat swab samples from 56 patients with clinically suspected bacterial pharyngitis were collected to evaluate the practicality of the GAS-MCDA-CRISPR method in clinical sample testing.
[0070] (2) McdA primer screening
[0071] The gene sequence of SpeB, a specific gene of GAS, was downloaded from NCBI, and a total of 6 sets of primers were designed. The sequences of the 6 sets of primers are shown in Tables 1-6.
[0072] Table 1 Sequences of the first set of primers
[0073]
[0074] Table 2 Sequences of the second set of primers
[0075]
[0076] Table 3 Sequences of the third set of primers
[0077]
[0078] Table 4 Sequences of the fourth set of primers
[0079]
[0080] Table 5 Sequences of the fifth set of primers
[0081]
[0082] Table 6 Sequences of the sixth set of primers
[0083]
[0084] The steps for screening these 6 sets of primers are as follows:
[0085] 1) Each set of primers was used to amplify GAS genomic DNA (9 pg / µL), the temperature was set to 63°C, the amplification time was 40 minutes, the turbidity generated by the accumulation of magnesium pyrophosphate (white precipitate formed during the MCDA reaction) was measured using a real-time turbidity method, and a kinetic turbidity curve was drawn to analyze the results, and primers with high amplification efficiency and good amplification effect were selected as the primer pairs required by the present invention, and the gRNA sequence was designed and verified based on the screened primer pairs for subsequent CRISPR-Cas12a detection.
[0086] 2) Reagent composition of MCDA amplification reaction
[0087] 25 µL reaction system: 0.4 µM primers F1 and F2, 1.6 µM primers CP1 and CP2, 0.8 µM primers C1, C2, D1, D2, R1, and R2, 12.5 µL 2× reaction buffer, 1.0 µL Bst 2.0 DNA polymerase, 1.0 µL nucleic acid sample, 8.3 µL double distilled water
[0088] Positive control: GAS genomic DNA
[0089] Negative control: Streptococcus pneumoniae genomic DNA
[0090] Blank control: double distilled water
[0091] 3) Figure 3-8 The amplification efficiency of the 6 sets of primers screened is shown. It can be seen that the first set of primers has the fastest turbidity value and the amplification efficiency is very ideal, and other primer combinations cannot achieve the above amplification efficiency. It is worth noting that the cross primer CP1 of the first set of primers has a PAM sequence (TTTG) that satisfies the basic conditions for the CRISPR-Cas12a diagnostic system to perform the cutting reaction. Therefore, the present invention will subsequently design gRNA for the amplified product of the first set of primers, and combine the CRISPR-Cas12a cutting system to verify whether the gRNA can guide the gRNA-Cas12a complex to specifically bind to the product of the first set of primers and activate the side chain cleavage activity of the Cas12a protease.
[0092] (3) Feasibility verification of the GAS-MCDA-CRISPR method
[0093] 1) Design the gRNA sequence based on the amplified product of the first set of primers selected above, and verify whether the gRNA can guide the gRNA-Cas12a complex to specifically bind to the product of the first set of primers and activate the side chain cleavage activity of the Cas12a protease in combination with the CRISPR-Cas12a cleavage system. The first set of primers and gRNA sequences are shown in Table 7, and the locations of the MCDA primer binding site and gRNA recognition site on the gene are shown in Fig. 9 shown.
[0094] Table 7 Primers, probes and gRNA sequences finally selected by the present invention
[0095]
[0096] 2) Reagent composition and detection steps for CRISPR-Cas12a detection
[0097] ①Synthesis of Cas12a-gRNA complex:
[0098] 100 nM Cas12a and 100 nM gRNA were mixed, added to 2×NEBuffer r2.1, and incubated at 37°C for 8-10 minutes. The prepared complex was stored at low temperature (0-4°C) for no more than 12 hours.
[0099] ②CRISPR-Cas12a detection system:
[0100] 50µL detection system, including 1µL MCDA product, 9µL CRISPR-Cas12a-gRNA complex, 1.25µL ssDNA probe (FAM-ATTATTATTATTT-BHQ1), 25µL 2×NEBuffer r2.1, double distilled water was added to the reaction system to 50µL. Then the mixture was incubated at 37°C for 5-15 minutes to shear ssDNA and release a large amount of fluorescent signal.
[0101] ③When the target product exists in the system, the side chain cleavage activity of Cas12a is activated, cleaving the ssDNA reporter and emitting a fluorescent signal. When the target product does not exist in the system, the ssDNA reporter cannot be cleaved and no fluorescent signal is released. Set the ABI7500 real-time fluorescence system to record the fluorescence value once a minute, or the fluorescent signal can be observed under blue light after the reaction is completed.
[0102] 3) Test results such as Fig.10 As shown in the figure, the real-time fluorescence instrument results showed that the reaction tube group containing the GAS amplification product showed a significant fluorescence signal value, while the negative control and blank control did not show any fluorescence signal ( Fig.10 A). The test tube containing the GAS amplification product can be directly observed by the naked eye under the irradiation of blue light, while no fluorescence reaction was observed in the negative control and blank control ( Fig.10 B). The above results indicate that the gRNA designed for the amplified product of the first set of primers can correctly guide the gRNA-Cas12a complex to specifically bind to the amplified product. It is preliminarily confirmed that the GAS-MCDA-CRISPR method established in the present invention can effectively detect GAS.
[0103] (4) Optimizing the temperature of the MCDA amplification reaction
[0104] The temperature range for MCDA reaction amplification is 59-68℃. The temperature has a critical impact on the amplification efficiency and the final amplification results. The appropriate temperature will greatly improve the amplification efficiency. This experiment sets 8 constant temperatures ranging from 60 to 67℃, with an interval of 1℃. The MCDA reaction system ratio is the same as above. The DNA template concentration used is 9pg per reaction, and double distilled water is used as a blank control. A turbidity meter (LA-320C) is used to draw a kinetic turbidity curve analysis result. The results are shown in Fig.11 As shown in the figure, when the temperature is 63°C, the amplification efficiency is the highest compared with other temperatures, so we judge that 63°C is the optimal temperature for MCDA amplification. In the subsequent MCDA amplification step, the conditions are set to 63°C for 40 minutes.
[0105] (5) Optimizing CRISPR-Cas12a cleavage time
[0106] In order to determine the shortest time required for CRISPR-Cas12a to cut the target product, we compared the detection efficiency of three different reaction times (5, 10 and 15 minutes) at 37°C, and determined the optimal cutting time by observing the fluorescence reaction under blue light using a real-time fluorescence instrument. Fig.12 In the figure, 1-7 represent the concentrations of DNA templates, which are 9 ng, 900 pg, 90 pg, 9 pg, 900 fg, 90 fg, 45 fg, and 22.5 fg, respectively, and 8 is a blank control group of double distilled water. The results show that a 5-minute reaction time is sufficient to complete the trans-cleavage step of the ssDNA probe. In the subsequent CRISPR-Cas12a cleavage step, the reaction conditions were set at 37°C for 5 minutes.
[0107] (6) Testing the sensitivity of the GAS-MCDA-CRISPR method
[0108] The sensitivity of this method was further determined to determine the lowest concentration of GAS genomic DNA that could be detected. The genomic DNA template was diluted continuously to concentrations of 9ng, 900pg, 90pg, 9pg, 900fg, 90fg, 45fg, and 22.5fg. 1µL of each diluted template was added to the reaction system, and distilled water was set as a blank control. The experimental results were determined by real-time fluorescence instrumentation and blue light irradiation of the reaction tube. The results are shown in Figure 2. Fig.13 As shown, when the concentration of the reaction tube is 45fg or above, a strong fluorescence signal can be detected, and no fluorescence signal is detected in the 22.5fg and blank control groups. The concentrations of the DNA templates 1-7 in the figure are 9ng, 900pg, 90pg, 9pg, 900fg, 90fg, 45fg, and 22.5fg, respectively, and curve 8 is a blank control. Therefore, the GAS-MCDA-CRISPR method can detect genomic DNA of pure cultured GAS as low as 45 fg per reaction.
[0109] (7) Testing the specificity of the GAS-MCDA-CRISPR method
[0110] The specificity of the GAS-MCDA-CRISPR method was studied. The samples to be tested are shown in Table 8. In this experiment, the optimal reaction conditions determined above were used to perform nucleic acid detection on 3 GAS samples and 28 non-GAS extracted nucleic acid templates. The reaction conditions of the MCDA amplification reaction and CRISPR-Cas12a detection steps were as described above. The results are shown in Table 8. Fig.14 As shown in the figure, only the test tube containing GAS genomic DNA showed a positive result, while the reaction tube without GAS showed a negative result. This shows that this protocol has strong specificity for GAS and meets the application requirements.
[0111] Table 8. Information on pathogens used in specific studies
[0112]
[0113]
[0114] CIP, Capital Institute of Pediatrics, ICDC, Chinese Center for Disease Control and Prevention
[0115] (8) Feasibility verification of GAS-MCDA-CRISPR method for clinical samples
[0116] To further verify whether the GAS-MCDA-CRISPR method can be used to detect clinical samples, we collected 56 throat swabs suspected of bacterial pharyngitis from the Children's Hospital Affiliated to Capital Institute of Pediatrics. The collected samples were first extracted with nucleic acid using the All-Gold EasyPure Bacterial Genomic DNA Kit (Enzymatic Hydrolysis) DNA Extraction Kit, and then detected using the GAS-MCDA-CRISPR method. At the same time, in order to verify the accuracy of this method, we also used real-time fluorescence PCR to detect these clinical samples and compared the results with the GAS-MCDA-CRISPR method. The upstream and downstream primer sequences and fluorescent probe sequences of PCR are as follows: SpeB-F: CGCACTAAACCCTTCAGCTCTT; SpeB-R: ACAGCACTTTGGTAACCGTTGA; SpeB-Probe: FAM-GCCTGCGCCGCCACCAGTA-BHQ1. The experimental results of the GAS-MCDA-CRISPR method are shown in Fig.15 The real-time fluorescence instrument detected 28 positive and 28 negative samples. After the reaction was completed, the reaction tube was illuminated by blue light and the same results were shown. The above results are completely consistent with the detection results of real-time fluorescence PCR (Table 9). Therefore, the detection method of this scheme can accurately reflect the infection status of clinical samples.
[0117] Table 9 Clinical sample test results
[0118]
[0119] In summary, the MCDA-CRISPR / Cas12a-based rapid detection method for Streptococcus pyogenes of the embodiment of the present invention combines the MCDA amplification technology with the CRISPR-Cas12a system for the detection of Streptococcus pyogenes; it solves the shortcomings of the existing detection method that the use is limited by the venue and is not routine. In addition, the operation process is simple, rapid, and has high amplification efficiency, which is expected to be an instant diagnostic method for GAS infection detection.
[0120] It should be noted that, in this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or device including the elements.
[0121] The above description is only a specific embodiment of the present invention, so that those skilled in the art can understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments described herein, but should conform to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A kit for detecting Streptococcus pyogenes, characterized in that: The kit comprises: McdA primer; The MCDA primers include a displacement primer pair, a cross primer pair, a first amplification primer pair, a second amplification primer pair, and a third amplification primer pair; The replacement primer pair includes a forward replacement primer F1 whose sequence is shown as SEQ ID NO.1 and a reverse replacement primer F2 whose sequence is shown as SEQ ID NO.2; The cross primer pair includes a forward cross primer CP1 whose sequence is shown in SEQ ID NO.3 and a reverse cross primer CP2 whose sequence is shown in SEQ ID NO.4; The first amplification primer pair includes a first reverse amplification primer D1 whose sequence is shown in SEQ ID NO.5 and a first forward amplification primer D2 whose sequence is shown in SEQ ID NO.6; The second amplification primer pair includes a second reverse amplification primer C1 whose sequence is shown in SEQ ID NO.7 and a second forward amplification primer C2 whose sequence is shown in SEQ ID NO.8; The third amplification primer pair includes a third reverse amplification primer R1 whose sequence is shown in SEQ ID NO.9 and a third forward amplification primer R2 whose sequence is shown in SEQ ID NO.10; gRNA; The sequence of the gRNA is shown in SEQ ID NO.11; Cas12a; and ssDNA fluorescent probe; The sequence of the ssDNA fluorescent probe is shown in SEQ ID NO.
12.
2. The kit according to claim 1, characterized in that The kit also includes: 2× reaction buffer, endonuclease reaction buffer, Bst 2.0 DNA polymerase and double distilled water; Wherein, the reaction buffer is a mixture of tris(hydroxymethyl)aminomethane hydrochloride, KCl, MgSO4, (NH4)2SO4, polyoxyethylene sorbitan monolaurate, (carboxymethyl)trimethylamine inner salt and deoxyribonucleotides; The endonuclease reaction buffer is a mixture of NaCl, tris(hydroxymethyl)aminomethane hydrochloride, MgCl2 and recombinant albumin.
3. A method for detecting Streptococcus pyogenes for non-diagnostic purposes using the kit according to claim 1 or 2, characterized in that: The method comprises: The multiple cross-displacement amplification method is used to amplify the DNA of the sample to be tested using MCDA primers to prepare an amplification product; gRNA and Cas12a protein complex to form a Cas12a-gRNA binary complex; The amplified product, the Cas12a-gRNA binary complex and the ssDNA fluorescent probe are incubated to obtain an incubation product; Detecting the fluorescent signal of the incubation product; Determine whether Streptococcus pyogenes is present.
4. The method according to claim 3, characterized in that The steps of the amplification reaction include: MCDA primer, 2× reaction buffer, Bst 2.0 A mixture of DNA polymerase, DNA of the sample to be tested, and double distilled water is reacted at 59-68°C.
5. The method according to claim 3, characterized in that: The steps of compounding the gRNA and Cas12a protein include: Cas12a and gRNA were mixed, added to the endonuclease reaction buffer, and incubated at 37°C for 8-10 minutes to obtain a Cas12a-gRNA binary complex.
6. The method according to claim 3, characterized in that The step of incubating the amplified product, the Cas12a-gRNA binary complex and the ssDNA fluorescent probe comprises: A mixture of amplified product, Cas12a-gRNA binary complex, ssDNA fluorescent probe, endonuclease reaction buffer and double distilled water was incubated at 37°C to shear the ssDNA fluorescent probe for 5-15 minutes.
7. The method according to claim 3, characterized in that The method for detecting the fluorescent signal of the incubation product comprises: The fluorescence value was detected using a real-time fluorescence system; Alternatively, observe the fluorescence signal under blue light after the incubation reaction is completed.
8. The method according to claim 3, characterized in that The method for determining whether Streptococcus pyogenes is present comprises: If a fluorescent signal is detected, there is Streptococcus pyogenes, and if no fluorescent signal is detected, there is no Streptococcus pyogenes.
Citation Information
Patent Citations
Method for amplifying nucleotide segment by multicross substitution and application thereof
CN104946744A
CRISPR / Cas12a one-step nucleic acid detection method
CN112695073A
CRISPR-Cas12a-based streptococcus suis rapid visual RPA detection kit and application thereof
CN113621717A
